Effect analysis of recombinant human epidermal growth factor derivative eye drops combined with sodium hyaluronate eye drops in the treatment of dry eye syndrome after cataract surgery
Objective:To investigate the clinical efficacy of recombinant human epidermal growth factor derivative eye drops combined with sodium hyaluronate eye drops in the treatment of dry eye syndrome after cataract surgery.Methods:100 patients with dry eye syndrome after cataract surgery at Weifang Eye Hospital were selected from March 2021 to March 2023,and were divided into observation group and control group by random number table method,with 50 patients in each group.The control group was treated with sodium hyaluronate eye drops,and the observation group was treated with recombinant human epidermal growth factor derivative eye drops combined with sodium hyaluronate eye drops.The clinical efficacy as well as ocular function indexes of the two groups were recorded.Results:The treatment efficiency of the observation group was as high as 96.00%,while that of the control group was only 68.00%.Meanwhile,compared to the control group,the observation group had a more stable tear film,longer rupture time,thicker tear film,and greater tear secretion.In addition,the corneal fluorescein staining score and the ocular surface disease index score of the observation group were lower than those of the control group in the assessment of corneal health.These differences were statistically significant(P＜0.05).However,there was no significant difference in the adverse reaction profile between the two groups(P＞0.05).Conclusion:The combination of recombinant human epidermal growth factor derivative eye drops and sodium hyaluronate eye drops is effective in treating dry eye syndrome after cataract surgery.This combination therapy not only improves the treatment efficacy,but also enhances the stability of the tear film and the health of the cornea,which brings good news for patients with dry eye syndrome after cataract surgery.
万方数据
维普
